Market Overview - On February 11, Hong Kong stocks opened higher and expanded gains, with the Hang Seng Index closing up 83 points (0.3%) at 27,266 points[1] - The Hang Seng Tech Index rose by 48 points (0.9%) to close at 5,499 points, with total market turnover reaching HKD 217.2 billion[1] - Southbound capital saw a net inflow of HKD 4.82 billion, compared to a previous day's net inflow of HKD 84.66 million[1] Key Stock Movements - Semiconductor company SMIC reported a 61% year-on-year increase in Q4 net profit, but its Q1 gross margin guidance fell short of expectations, leading to a 2.1% drop in its stock price[1] - Precious metal stocks saw gains, with Zijin Mining up 2.8%, Shandong Gold up 4.4%, and Zijin Gold International up 9.1%[1] - Xiaomi's stock rose 4.3% after it invested in a humanoid robot parts supplier, while other automotive stocks like BYD and Geely also saw increases of 2.7% to 3.9%[4] Economic Indicators - In the U.S., January non-farm payrolls increased by 130,000, significantly above the expected 65,000, with the unemployment rate dropping to 4.3% from 4.4% in December[2] - China's January PPI fell by 1.4% year-on-year, slightly better than the expected 1.5% decline, while CPI rose by 0.2% year-on-year, below the expected 0.4%[3] Sector Performance - The healthcare sector saw a 0.7% increase in the Hang Seng Healthcare Index, with WuXi Biologics forecasting a 16.7% revenue growth to HKD 21.79 billion for 2025[4] - The renewable energy and utilities sector generally rose, with Huaneng International and Datang Power increasing by 1.7% to 2.4%[5]

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

Core Insights - Singapore attracted 14.2 billion SGD in fixed asset investments in 2025, marking a 5.2% year-on-year increase despite global geopolitical and economic challenges [1] - Chinese investments surged, increasing from 2.5% in 2024 to 20.6% in 2025, surpassing the US to become Singapore's second-largest investment source after Europe [1] Investment Structure - Of the 14.2 billion SGD in fixed asset investment commitments, approximately 12.1 billion SGD came from manufacturing-related projects, accounting for 85% [2] - Semiconductor manufacturing led the investments, contributing 33% of the fixed asset investments, driven by the explosive growth in global AI demand [2] - Investments in biopharmaceutical manufacturing, specialty chemicals, sustainable materials, and aerospace maintenance also saw significant interest from Chinese enterprises [2] Strategic Shifts in Operations - 55% of surveyed Chinese enterprises rated Singapore's business environment as "excellent," with public services and financial systems being key attractions [3] - The strategic positioning of Chinese enterprises in Singapore has evolved from a "springboard" to a "regional headquarters hub," with over 70% viewing the Johor-Singapore Economic Zone as vital for capacity expansion and cost management [3] Full Industry Chain Ecosystem - Chinese companies are establishing a comprehensive industry chain ecosystem in Singapore, with firms like ByteDance and Ant Group setting up regional headquarters [4] - This integrated model of "R&D + manufacturing + sales + financial management" signifies a shift from simple market expansion to global value chain restructuring [4] - Singapore's role as an international financial center facilitates comprehensive financial services for Chinese enterprises, reducing reliance on the US dollar system [4] Regional Economic Integration - The influx of Chinese investments in Singapore reflects the accelerating economic integration between China and Southeast Asia [5] - The model of "Singapore base + ASEAN manufacturing + global sales" is being replicated in countries like Vietnam and Malaysia, reshaping the global supply chain geography [5] Future Outlook - The investment trend from Chinese enterprises in Singapore is expected to continue, driven by factors such as the advancement of the China-Singapore Free Trade Agreement and Singapore's role in digital currency trials [6] - Despite potential challenges, the Singapore model remains a preferred strategy for Chinese enterprises to navigate trade barriers and expand into global markets [6]

传媒板块大涨，数字王国大涨29%，阅文集团涨逾15%，大麦娱乐涨超6%。 | 名称 | 涨跌幅 ▼ | 现价 | | --- | --- | --- | | 数字于国 | 29.31% | 0.375c | | 毛记葵涌 | 21.92% | 0.890c | | 万咖膏联 | 20.00% | 1.560c | | 中国国家文化产业 | 18.18% | 0.780c | | 阅文集团 | 15.41% | 43.580c | | 环球数码创意 | 9.09% | 0.072c | | 普乐师集团控股 | 8.76% | 5.710c | | 橙天嘉禾 | 7.81% | 0.069c | | 大麦娱乐 | 6.12% | 1.040c | | 新传企划 | 5.71% | 0.370c | | 中国儒意 | 5.63% | 2.250c | | 柠萌影视 | 5.42% | 3.500c | | 乐思集团 | 4.81% | 1.090c | | 丰德丽控股 | 4.17% | 0.050c | | 稻草熊娱乐 | 3.75% | 0.415c | | 大象未来集团 | 3.72% | 2.230c | ...

2月11日，港股医药有所分化。创新药大面积回调，创新药纯度100%的港股通创新药ETF（520880）微 跌0.19%止步三连阳。医疗主题板块继续上行，港股通医疗ETF华宝（159137）走出四连涨，站上20日 均线。 | 分时 多日 1分 5分 15分 30分 · 给会屏 F9 后复农 超级盘加 面试 工具 @ (1) > | | 港般通医疗ETF华宝 | | 159137 | | --- | --- | --- | --- | --- | | 159137.SZ[桃投通四疗ETF华宜] 2026/02/11 歌 1.024 幅0.49%(0.005) 开 1.025 高 1.030 低 1.019 均回 | | | | | | MAS 1.0021 MA10 0.998 MA20 1.022 2026/01/12-2026/02/11(23日)▼ | | 0 | | +0.005 +0.499 | | | 1,160 | SZSE CNY 15:00:00 闭槽 | | T+0 / 0 | | 4-1,152 | | 净值走势 | | 华宝中证港股通医疗主题ETF | | | | DEF | -51.86 ...

Market Overview - The Hong Kong stock market showed positive movement with the Hang Seng Index rising by 0.31% to close at 27,266.38 points, while the Hang Seng Tech Index increased by 0.90% to 5,499.99 points, and the Hang Seng China Enterprises Index rose by 0.28% to 9,268.18 points [2] - The total market turnover was HKD 217.22 billion, a decrease from the previous trading day's turnover of HKD 234.04 billion [2] Stock Performance - Among the constituents of the Hang Seng Index, 62 stocks rose while 23 fell. Notable gainers included: - Techtronic Industries, up 4.90% with a turnover of HKD 2.105 billion and a year-to-date increase of 33.37% [3][4] - Xiaomi Group, up 4.27% with a turnover of HKD 8.259 billion and a year-to-date decrease of 5.60% [4] - Link REIT, up 3.83% with a turnover of HKD 1.136 billion and a year-to-date increase of 6.16% [4] - On the downside, Pop Mart fell by 5.49%, China Life by 3.94%, and Shenzhou International by 2.22% [3] Regulatory Alert - The Hong Kong Securities and Futures Commission (SFC) issued a warning about fraudulent stock analysts impersonating reputable figures to promote high-return investment schemes, leading to potential scams [5][6] - The SFC has reported cases where fraudsters use social media to lure victims into "pump and dump" schemes, where they artificially inflate stock prices before selling off their shares [6][7] - The SFC has filed a report with the police and is collaborating with law enforcement to combat investment fraud [7] Company Financials - NetEase reported a total revenue of RMB 112.6 billion for the year, with Q4 revenue of RMB 27.5 billion. The company achieved an operating profit of RMB 35.8 billion for the year, a 21% increase year-on-year [10] - The gaming and related services revenue reached RMB 92.1 billion, with online gaming net revenue of RMB 89.6 billion, marking an 11% year-on-year growth [10] - Semiconductor manufacturer SMIC reported a net profit increase of 60.7% year-on-year, despite a stock price decline of over 2% following the earnings announcement [10][13]

Core Viewpoint - The Hang Seng Index rose by 0.31%, while the Hang Seng Tech Index increased by 0.9% [1] Group 1: Company Performance - Bilibili saw an increase of over 5% in its stock price [1] - Tencent Music, Xiaomi Group, and Kingdee International each rose by over 4% [1] - BYD Company, WuXi Biologics, and New Oriental Education experienced gains of over 3% [1] Group 2: Company Declines - Pop Mart International fell by over 5% [1] - China Life Insurance declined by nearly 4% [1]

2月11日，港股收盘， 恒生指数收涨0.31%，恒生科技指数收涨0.9%。 有色金属、稀土永磁板块上涨，赤峰黄金涨近6%，山东黄金涨4.4%，金力永磁涨5%，赣锋锂业涨5.5%。 | 黄金珠宝 | 水泥 | 雄安新区 | 智能建筑 | 贵金属 | | --- | --- | --- | --- | --- | | 6.02% | 4.70% | 4.58% | 4.34% | 4.28% | | 智能家居 | 智能终端 | 电讯设备 | 充电桩 | 燃料电池 | | 4.27% | 3.70% | 3.53% | 3.48% | 3.38% | | 芯片 | 工业4.0 | 令日头条系 | GEO | 文化传媒 | | -1.68% | -1.73% | -1.87% | -1.90% | -1.93% | | 彩票 | 成电路产业基 | 中资保险 | 影视传媒 | 恋宴 | | -2.01% | -2.05% | -2.11% | -2.72% | -3.42% | 光通信、cpo等板块回落，长飞光纤光缆跌近6%，剑桥科技跌5.7%。 在一般的"唱高散货"骗局中，骗徒会冒充为知名投资专家，集中推介及"唱高" ...

Core Viewpoint - WuXi Biologics (02269) has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with expectations, while net profit is projected to increase by 38% to 2.6 billion RMB, significantly exceeding market forecasts [1] Financial Performance - Adjusted net profit is expected to rise by 31% to 3.7 billion RMB, which is also well above market expectations [1] - Gross margin has increased by 6.2 percentage points to 48.8%, identified as a key positive surprise in the earnings upgrade and a major driver of the better-than-expected profit performance [1] Market Position - In the Chinese contract research organization (CRO) and contract development and manufacturing organization (CDMO) sectors, WuXi Biologics remains a top pick [1]

每经记者｜马原 每经编辑｜程鹏 记者|马原 编辑|程鹏 杜恒峰 校对|许绍航 2月11日，港股收盘， 恒生指数收涨0.31%，恒生科技指数收涨0.9%。 有色金属、稀土永磁板块上涨，赤峰黄金涨近6%，山东黄金涨4.4%，金力永磁涨5%，赣锋锂业涨5.5%。 | 黄金珠宝 | 水泥 | 雄安新区 | 智能建筑 | 贵金属 | | --- | --- | --- | --- | --- | | 6.02% | 4.70% | 4.58% | 4.34% | 4.28% | | 智能家居 | 智能终端 | 电讯设备 | 充电桩 | 燃料电池 | | 4.27% | 3.70% | 3.53% | 3.48% | 3.38% | | 芯片 | 工业4.0 | 令日头条系 | GEO | 文化传媒 | | -1.68% | -1.73% | -1.87% | -1.90% | -1.93% | | 彩票 | 成电路产业基 | 中资保险 | 影视传媒 | 恋宴 | | -2.01% | -2.05% | -2.11% | -2.72% | -3.42% | 光通信、cpo等板块回落，长飞光纤光缆跌近6%，剑桥科技跌5.7 ...